News Quantified

MGNX – macrogenics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

MacroGenics (NASDAQ:MGNX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

MacroGenics (NASDAQ:MGNX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.

Results: MacroGenics, Inc. Confounded Analyst Expectations With A Surprise Profit [Yahoo! Finance]

7.8%

BEAT

-2.5%

BEAT

0.6%

MISS

Form 8-K MACROGENICS INC For: Nov 14

Form 8-K MACROGENICS INC For: Nov 12

Form 10-Q MACROGENICS INC For: Sep 30

Form SCHEDULE 13G/A MACROGENICS INC Filed by: WASATCH ADVISORS LP

Top News Gainers

3/9 Form 4 MACROGENICS INC For: Mar 06 Filed by: Karrels James 10.7%

5/15 MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer 10.4%

12/12 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $50.00 price target on the stock. 9.9%

3/23 Form PRE 14A MACROGENICS INC For: May 14 9.8%

4/17 Form 4 MACROGENICS INC For: Apr 16 Filed by: Risser Eric Blasius 8.5%

3/26 MacroGenics Inc (NASDAQ: MGNX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 7.9%

11/21 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. 7.9%

2/25 MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.7%

1/13 MacroGenics to Present at the J.P. Morgan Healthcare Conference 7.2%

12/11 MacroGenics down 3% on uncertainty of margetuximab survival benefit [Seeking Alpha] 6.6%

Top News Decliners

3/13 Form 4 MACROGENICS INC For: Mar 11 Filed by: Koenig Scott -20.5%

6/3 MacroGenics: Updating The Investment Thesis [Seeking Alpha] -17.1%

2/27 MacroGenics to Participate in Upcoming Investor Conferences -15.7%

10/22 MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer -15.3%

2/28 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.4%

3/7 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -11.9%

3/17 Form 4 MACROGENICS INC For: Mar 13 Filed by: Risser Eric Blasius -9.1%

3/4 MacroGenics Announces Departure of Chief Medical Officer -8.5%

3/25 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.5%

6/5 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -5.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day